Clarus Ventures, a life sciences investment firm, has appointed Kiran Reddy and Robert DeBenedetto to Venture Partner, and Lazar Dimitrov to Associate. Based in the firm’s Cambridge, Mass. office, Reddy will focus on both new company formation and risk-sharing partnerships with pharmaceutical companies. DeBenedetto and Dimitrov will be based in Clarus’ South San Francisco, Calif. office.
Reddy joined from Biogen’s Corporate Strategy team where he focused on strategic transactions. Prior to Biogen, he was an Associate Partner at Third Rock Ventures (TRV) and co-founded several startups, including Foundation Medicine and Sage Therapeutics, where he served as Chief Business Officer.
“Reddy brings deep expertise and experience in clinical neurology and company formation. He complements and expands our investment platform across all aspects of our investment activities,” stated Nicholas Galakatos, Managing Director at Clarus.
With over 25 years of global pharmaceutical and life sciences experience, DeBenedetto is currently CEO of SFJ Pharmaceuticals, which he founded in January 2009. Prior to founding SFJ, he was Vice President of Global Business Development at Quintiles Pharmaceuticals investment unit and served as Executive Committee Member, Chief Financial Officer, Vice President of Corporate Development, and Vice President of Corporate Marketing for Boston Scientific’s Japan subsidiary.
Clarus Managing Director Kurt Wheeler said, “DeBenedetto provides Clarus with additional experience in funding and developing risk-sharing partnerships with major pharmaceutical companies to bring late stage pharmaceuticals to market. His expertise strengthens Clarus’ ability to structure these unique partnerships.”
Dimitrov previously worked for Blue Matter Consulting, where he advised clients on their immuno-oncology strategies. Prior to this, he was a scientist at Crystal Bioscience, where he managed the research & development pipeline and new business development.
Founded in 2005, Clarus manages over USD1.7 billion and has invested in more than 50 private and public companies in the biotechnology, medical device and diagnostic spaces.